NCT06379360
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients: A Single Arm, Multi Center Clinical Trial
The First Affiliated Hospital of Soochow University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Acute Myeloid Leukemia
- Drug/Device/Intervention
- Hypomethylating agent, Azacitidine or Decitabine
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- The First Affiliated Hospital of Soochow University
- Location
- Suzhou, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Nov 01, 2020
- End date
- Dec 31, 2028
- Enrollment
- 77 participants
Primary outcome
Relapse free survival (RFS)
Summary
HMA maintenance therapy is expected to benefit overall survival (OS) and relapse free
 survival (RFS) in AML patients with favorable risk.
ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06379360
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06379360 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Soochow University and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 77 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.